UNIVERSITY OF NEBRASKA MEDICAL CENTER
Co-targeting IGF-1R and Glutaminase in Ewing Sarcoma
Co-targeting IGF-1R and Glutaminase in Ewing Sarcoma is a funding opportunity from UNIVERSITY OF NEBRASKA MEDICAL CENTER, up to 391186, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY Aberrant activation of receptor tyrosine kinases (RTK) drives or enables tumorigenesis, metastasis, and therapeutic resistance across cancers but RTK targeting is only successful in few of these. IGF-1R provides a key oncogenic axis in Ewing Sarcoma (EWS), the second most common malignant bone tumor of…